Phase 1b: APG-115+pembrolizumab

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Unresectable or Metastatic Melanoma or Advanced Solid Tumors

Drug Information

Target Indication

Unresectable or Metastatic Melanoma or Advanced Solid Tumors

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

Related Pipeline

Higher-risk Myelodysplastic Syndrome

CLL/SLL

Relapsed/Refractory Acute Myeloid Leukaemia

GIST

CLL/SLL